236 related articles for article (PubMed ID: 36018781)
1. Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients.
Burman P; Trouillas J; Losa M; McCormack A; Petersenn S; Popovic V; Theodoropoulou M; Raverot G; Dekkers OM;
Eur J Endocrinol; 2022 Oct; 187(4):593-605. PubMed ID: 36018781
[TBL] [Abstract][Full Text] [Related]
2. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.
McCormack A; Dekkers OM; Petersenn S; Popovic V; Trouillas J; Raverot G; Burman P;
Eur J Endocrinol; 2018 Mar; 178(3):265-276. PubMed ID: 29330228
[TBL] [Abstract][Full Text] [Related]
3. [Aggressive pituitary adenoma and pituitary carcinoma].
Tóth M
Orv Hetil; 2023 Jul; 164(30):1167-1175. PubMed ID: 37516994
[TBL] [Abstract][Full Text] [Related]
4. Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment.
Burman P; Casar-Borota O; Perez-Rivas LG; Dekkers OM
J Clin Endocrinol Metab; 2023 Jun; 108(7):1585-1601. PubMed ID: 36856733
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.
Lamas C; Cámara R; Fajardo C; Remon-Ruiz P; Biagetti B; Guerrero-Pérez F; Araujo-Castro M; Mora M; Hanzu F; Iglesias P; García-Centeno R; Soto A
Front Endocrinol (Lausanne); 2023; 14():1204206. PubMed ID: 37720528
[TBL] [Abstract][Full Text] [Related]
6. Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
Lizzul L; Lombardi G; Barbot M; Ceccato F; Gardiman MP; Regazzo D; Bellu L; Mazza E; Losa M; Scaroni C
Pituitary; 2020 Aug; 23(4):359-366. PubMed ID: 32232709
[TBL] [Abstract][Full Text] [Related]
7. Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression.
Demarchi G; Perrone S; Esper Romero G; De Bonis C; Casasco JP; Sevlever G; Berner SI; Cristina C
Front Endocrinol (Lausanne); 2022; 13():870172. PubMed ID: 35928898
[TBL] [Abstract][Full Text] [Related]
8. Early recognition of aggressive pituitary adenomas: a single-centre experience.
Ceccato F; Regazzo D; Barbot M; Denaro L; Emanuelli E; Borsetto D; Rolma G; Alessio L; Gardiman MP; Lombardi G; Albiger N; D'Avella D; Scaroni C
Acta Neurochir (Wien); 2018 Jan; 160(1):49-55. PubMed ID: 29170844
[TBL] [Abstract][Full Text] [Related]
9. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
Annamalai AK; Dean AF; Kandasamy N; Kovacs K; Burton H; Halsall DJ; Shaw AS; Antoun NM; Cheow HK; Kirollos RW; Pickard JD; Simpson HL; Jefferies SJ; Burnet NG; Gurnell M
Pituitary; 2012 Sep; 15(3):276-87. PubMed ID: 22076588
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide in aggressive pituitary tumours and pituitary carcinomas.
McCormack A
Best Pract Res Clin Endocrinol Metab; 2022 Dec; 36(6):101713. PubMed ID: 36274026
[TBL] [Abstract][Full Text] [Related]
12. Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).
Lenders N; McCormack A
Pituitary; 2018 Apr; 21(2):217-229. PubMed ID: 29299820
[TBL] [Abstract][Full Text] [Related]
13. Aggressive corticotroph tumors and carcinomas.
Lasolle H; Vasiljevic A; Jouanneau E; Ilie MD; Raverot G
J Neuroendocrinol; 2022 Aug; 34(8):e13169. PubMed ID: 35979732
[TBL] [Abstract][Full Text] [Related]
14. Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study.
Ilie MD; Villa C; Cuny T; Cortet C; Assie G; Baussart B; Cancel M; Chanson P; Decoudier B; Deluche E; Di Stefano AL; Drui D; Gaillard S; Goichot B; Huillard O; Joncour A; Larrieu-Ciron D; Libe R; Nars G; Vasiljevic A; Raverot G
Eur J Endocrinol; 2022 Nov; 187(5):685-696. PubMed ID: 36111659
[TBL] [Abstract][Full Text] [Related]
15. Medical Therapy of Aggressive Pituitary Tumors.
Petersenn S
Exp Clin Endocrinol Diabetes; 2021 Mar; 129(3):186-193. PubMed ID: 33690871
[TBL] [Abstract][Full Text] [Related]
16. Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.
Yamamoto M; Nakao T; Ogawa W; Fukuoka H
Front Endocrinol (Lausanne); 2021; 12():650791. PubMed ID: 34220707
[TBL] [Abstract][Full Text] [Related]
17. Responses to corticotrophin-releasing hormone and dexamethasone in a large series of human adrenocorticotrophic hormone-secreting pituitary adenomas in vitro reveal manifold corticotroph tumoural phenotypes.
Pecori Giraldi F; Pagliardini L; Cassarino MF; Losa M; Lasio G; Cavagnini F
J Neuroendocrinol; 2011 Dec; 23(12):1214-21. PubMed ID: 21883533
[TBL] [Abstract][Full Text] [Related]
18. Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently.
Bradley KJ; Wass JA; Turner HE
Clin Endocrinol (Oxf); 2003 Jan; 58(1):59-64. PubMed ID: 12519413
[TBL] [Abstract][Full Text] [Related]
19. Aggressive pituitary tumours and pituitary carcinomas.
Raverot G; Ilie MD; Lasolle H; Amodru V; Trouillas J; Castinetti F; Brue T
Nat Rev Endocrinol; 2021 Nov; 17(11):671-684. PubMed ID: 34493834
[TBL] [Abstract][Full Text] [Related]
20. Aggressive pituitary adenomas--diagnosis and emerging treatments.
Di Ieva A; Rotondo F; Syro LV; Cusimano MD; Kovacs K
Nat Rev Endocrinol; 2014 Jul; 10(7):423-35. PubMed ID: 24821329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]